FindTrial
Sign In

ADCT-301

DRUG3 trials

Sponsors

ADC Therapeutics S.A., Gwynn Long, M.D.

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Bladder CancerColo-rectal CancerEsophageal CancerFallopian Tube CancerGastric Cancer

Phase 1

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
TerminatedNCT02588092
ADC Therapeutics S.A.Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Start: 2016-02-01End: 2018-08-29Updated: 2020-02-26
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
TerminatedNCT03621982
ADC Therapeutics S.A.Bladder Cancer, Colo-rectal Cancer, Esophageal Cancer +9
Start: 2018-11-09End: 2022-12-14Updated: 2024-06-13

Phase 2

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
TerminatedNCT04639024
Gwynn Long, M.D.Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
Start: 2021-12-07End: 2022-11-03Updated: 2026-05-01

Related Papers

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Cancer Research Communications2025-02-219 citations
608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
Regular and Young Investigator Award Abstracts2023-10-312 citations
Abstract 4151: Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors
Cancer Research2022-06-151 citations
A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology2021-05-206 citations
Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models
Blood2020-11-049 citations
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
Journal for ImmunoTherapy of Cancer2020-09-0176 citations
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
2020-06-0728 citations
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES
Hematological Oncology2019-06-016 citations
Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia
Blood2017-12-079 citations
A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.
Journal of Clinical Oncology2016-05-202 citations